or 12 months. - If unprovoked proximal DVT and symptomatic PE, indefinite anticoagulation for life. - When recurrent venous thromboembolism with or without anticoagulation, indefinite anticoagulation for life. ## Nursing, Allied Health, and Interprofessional Team Interventions - Educate at-risk patients on the disease condition and precautionary measures to minimize bleeding risk like avoiding suppositories, careful tooth brushing. - Encourage ambulation and activities to keep patients in chairs and out of bed for hospitalized patients or use mechanical compression devices if no contraindication. - Skin and mucosal inspection for petechiae, purpura, and open wounds. ## Nursing, Allied Health, and Interprofessional Team Monitoring Encourage close monitoring of patients on anticoagulation suspected of bleeding. This includes: - Monitoring hemoglobin serially - Monitoring heart rate and blood pressure, and electrocardiogram - Administering blood products if indicated - Monitor for indicators of internal bleeding like back, joint, or flank pain - Monitor for dark or smoky colored urine - Minimize unnecessary intravenous line placement or venipuncture ## Review Questions - [Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=17685&utm_source=pubmed&utm_campaign=reviews&utm_content=17685) - [Click here for a simplified version.](https://mdsearchlight.com/therapeutics/anticoagulation-anticoagulation-therapy/?utm_source=pubmedlink&utm_campaign=MDS&utm_content=17685) - [Comment on this article.](https://www.statpearls.com/articlelibrary/commentarticle/17685/?utm_source=pubmed&utm_campaign=comments&utm_content=17685) ## References 1. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1687-93. \[[PubMed: 17556654](https://pubmed.ncbi.nlm.nih.gov/17556654)\] 2. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: Which? Where? When? Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):1989-96. \[[PMC free article: PMC2783287](/pmc/articles/PMC2783287/)\] \[[PubMed: 19592470](https://pubmed.ncbi.nlm.nih.gov/19592470)\] 3. Gailani D, Renn√© T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2507-13. \[[PubMed: 17916770](https://pubmed.ncbi.nlm.nih.gov/17916770)\] 4. Marshall AL. Diagnosis, treatment, and prevention of venous thromboembolism in pregnancy. Postgrad Med. 2014 Nov;126(7):25-34. \[[PubMed: 25387211](https://pubmed.ncbi.nlm.nih.gov/25387211)\] 5. Antoniou S. Rivaroxaban for the treatment and prevention of thromboembolic disease. J Pharm Pharmacol. 2015 Aug;67(8):1119-32. \[[PubMed: 26059702](https://pubmed.ncbi.nlm.nih.gov/26059702)\] 6. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016 Jan;41(1):206-32. \[[PMC free article: PMC4715848](/pmc/articles/PMC4715848/)\] \[[PubMed: 26780747](https://pubmed.ncbi.nlm.nih.gov/26780747)\] 7. Barr D, Epps QJ. Direct oral anticoagulants: a review of common medication errors. J Thromb Thrombolysis. 2019 Jan;47(1):146-154. \[[PubMed: 30298305](https://pubmed.ncbi.nlm.nih.gov/30298305)\] 8. Zeballos-Palacios CL, Hargraves IG, Noseworthy PA, Branda ME, Kunneman M, Burnett B, Gionfriddo MR, McLeod CJ, Gorr H, Brito JP, Montori VM., Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial Investigators. Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing